Regeneron

Which asthma biologic do docs prefer? It's not that simple: analyst
Which asthma biologic do docs prefer? It's not that simple: analyst
Fierce Pharma
asthma
Roche
Novartis
Xolair
Sanofi
Regeneron
Dupixent
physicians
Flag link:
Sanofi and Regeneron's medical congress campaign focuses on type 2 inflammation education for docs
Sanofi and Regeneron's medical congress campaign focuses on type 2 inflammation education for docs
Fierce Pharma
Sanofi Genzyme
Regeneron
Dupixent
inflammation
Flag link:
Regeneron Pharmaceuticals Earnings: REGN Stock Rockets 7% on Q3 Beat
Regeneron Pharmaceuticals Earnings: REGN Stock Rockets 7% on Q3 Beat
Investor Place
Regeneron
earnings
Flag link:
Regeneron defends bid to challenge Merck in lung cancer
Regeneron defends bid to challenge Merck in lung cancer
Biopharma Dive
Regeneron
Libtayo
Merck
Keytruda
immuno-oncology
lung cancer
Flag link:
Regeneron profit beats expectations on Eylea, Dupixent strength
Regeneron profit beats expectations on Eylea, Dupixent strength
Yahoo/Reuters
Regeneron
earnings
Eylea
Dupixent
Flag link:
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
Drug/Biotech Stocks Nov 5 Earnings Roster: AGN, REGN & More
Yahoo/Zacks.com
Allergan
Regeneron
Mylan
Catalent
Jazz Pharmaceuticals
Flag link:
Eylea could be in trouble, but that doesn't make Regeneron a buyer
Eylea could be in trouble, but that doesn't make Regeneron a buyer
Biopharma Dive
Regeneron
M&A
Eylea
Flag link:
Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field
Glenmark spin-out aims to challenge Amgen, others in cancer bispecific field
Biopharma Dive
Glenmark
Ichnos Sciences
India
Amgen
oncology
Regeneron
bispecific antibodies
Flag link:
Pfizer posts detailed phase 3 data on its Dupixent rival
Pfizer posts detailed phase 3 data on its Dupixent rival
Fierce Biotech
Pfizer
clinical trials
atopic dermatitis
abrocitinib
Dupixent
Sanofi
Regeneron
Flag link:
Eylea casts a shadow over Novartis' latest approval
Eylea casts a shadow over Novartis' latest approval
Biopharma Dive
Novartis
Beovu
wet age-related macular degeneration
Regeneron
Eylea
Flag link:
Novartis backs brolucizumab with new head-to-head Eylea trial
Novartis backs brolucizumab with new head-to-head Eylea trial
Pharmaforum
Novartis
clinical trials
brolucizumab
Eylea
Bayer
Regeneron
age-related macular degeneration
Flag link:
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha
Fierce Pharma
Sanofi
Regeneron
Amgen
PCSK9 inhibitors
patents
Praluent
Repatha
Flag link:
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Fierce Pharma
Amgen
Regeneron
Sanofi
Praluent
Repatha
Medicines Company
PCSK9 inhibitors
inclisiran
Flag link:
What happened a year ago this week in biopharma? August 12-18, 2018
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Flag link:
What happened a year ago this week in biopharma? August 12-18, 2018
What happened a year ago this week in biopharma? August 12-18, 2018
CP WIre
Regeneron
Novartis
wet-AMD
Eylea
ethics
Vertex Pharmaceuticals
Kalydeco
cystic fibrosis
Bristol-Myers Squibb
Opdivo
Merck
Keytruda
SCLC
Flag link:
Regeneron plots $800M New York production push—along with 1,500 new jobs
Regeneron plots $800M New York production push—along with 1,500 new jobs
Fierce Pharma
Regeneron
drug manufacturing
New York
Flag link:
Regeneron drug proves effective in genetic form of high cholesterol
Regeneron drug proves effective in genetic form of high cholesterol
Stat
Regeneron
Homozygous Familial Hypercholesterolemia
evinacumab
Flag link:
Regeneron gets FDA approval for Eylea injection prefilled syringe
Regeneron gets FDA approval for Eylea injection prefilled syringe
Ophthalmology Times
Regeneron
Eylea
FDA
Flag link:
Regeneron's Ebola treatment proves superior to rival in trial
Regeneron's Ebola treatment proves superior to rival in trial
Yahoo/Reuters
Regeneron
Ebola
Mapp Biopharmaceutical
REGN-EB3
Flag link:
Dupixent brings long-awaited profits to Sanofi, Regeneron partnership
Dupixent brings long-awaited profits to Sanofi, Regeneron partnership
BioPharma Dive
Sanofi
Regeneron
Dupixent
Flag link:

Pages